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Small Molecule Integrin Antagonists that Bind to
the 2 Subunit I-like Domain and Activate Signals
in One Direction and Block Them in the Other
/ Rossmann fold with a metal ion-dependent adhe-
sion site (MIDAS) on the “top” of the domain, whereas
its C- and N-terminal connections to the neighboring
domain are on the distal, “bottom” face (Huang et al.,
2000; Lee et al., 1995; Shimaoka et al., 2002; Xiong
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200 Longwood Avenue et al., 2001). L2 binds its immunoglobulin superfamily
Boston, Massachusetts 02115 ligand ICAM-1 through the L I domain, with the binding
2 Novartis Pharma AG site centered on the Mg2 of the MIDAS which directly
Preclinical Research coordinates to Glu34 of ICAM-1 (Shimaoka et al., 2003).
Basel CH-4002 The affinity of the L I domain for ICAMs is regulated by
Switzerland downward axial displacement of its C-terminal helix,
which is conformationally linked to alterations of MIDAS
loops and Mg2 coordination (Huth et al., 2000; Shi-
Summary maoka et al., 2001, 2003). Compared to the default, low-
affinity conformation, downward displacements by one
Leukocyte integrins contain an inserted (I) domain in and two turns of helix increase affinity500- and 10,000-
their subunits and an I-like domain in their2 subunit, fold, respectively (Shimaoka et al., 2003). The 2 I-like
which directly bind ligand and regulate ligand binding, domain does not directly bind ligand despite containing
respectively. We describe a novel mechanistic class of a MIDAS motif. Instead, it functions indirectly by regulat-
integrin inhibitors that bind to the metal ion-dependent ing the activity of the I domain (Leitinger and Hogg,
adhesion site of the 2 I-like domain and prevent its 2000; Lu et al., 2001b, 2001c; Shimaoka et al., 2001;
interaction with and activation of the L I domain. The Yalamanchili et al., 2000).
inhibitors do not bind to the L I domain but stabilize At least two distinct classes of potent, low molecular
/ subunit association and can show selectivity for weight L2 antagonists are under development as anti-
L2 compared to M2. The inhibitors reveal a crucial inflammatory agents (Figure 1). One group of antago-
intersection for relaying conformational signals within
nists binds underneath the C-terminal  helix of the L Iintegrin extracellular domains. While blocking signals
domain (e.g., LFA703 or BIRT377), blocks the downward
in one direction to the I domain, the antagonists induce
axial displacement of the C-terminal helix, and inhibits
the active conformation of the I-like domain and stalk
ligand binding of L2 allosterically by stabilizing the Idomains, and thus transmit conformational signals in
domain in the low-affinity conformation (Kallen et al.,the other direction toward the transmembrane do-
1999; Last-Barney et al., 2001; Liu et al., 2001; Lu etmains.
al., 2001c; Weitz-Schmidt et al., 2001). By contrast, a
second class of compounds, which has been patentedIntroduction
as L2 antagonists by Genentech (Burdick, 1999; Bur-
dick et al., 2001) and dual-acting L2 and M2 antago-LFA-1 (L2) is a member of the leukocyte integrin sub-
nists (Fotouhi et al., 1999) or L2 antagonists (Fotouhifamily that shares the 2 subunit with Mac-1 (M2),
et al., 2001) by Roche, remains less defined with regardp150,95 (X2), and D2 (Gahmberg et al., 1997; Harris
to the binding site and mode of action. Genentech com-et al., 2000). L2 plays a critical role in leukocyte adhe-
pounds #3 and #4 (Figure 1A) were reported to be ratio-sion to and migration through endothelium by its ability
nally designed based on the structure of ICAM-1 byto bind intercellular adhesion molecules (ICAMs), espe-
grafting amino acid residue functionalities that were dis-cially ICAM-1, on endothelial cells. L2 is also crucial
tant in amino acid sequence but contiguous in three-for lymphocyte adhesion and costimulation, and for for-
dimensional structure onto a small molecule antagonistmation of the immunological synapse between T and
(Gadek et al., 2002). Thus, it was implied, but not demon-antigen-presenting cells (Grakoui et al., 1999). Further-
strated, that the antagonists bound like ICAM-1 to themore, L2 is an important pharmaceutical target for
L I domain. However, studies with a structurally related,blocking rejection in organ transplantation and treating
dual L2 and M2 inhibitor from Roche (Figure 1A)autoimmune diseases. Monoclonal antibodies to L2
showed it did not perturb NMR chemical shifts of iso-prolong graft survival in many animal models (Nicolls et
latedL orM I domains, but did perturb antibody bindingal., 2002; Poston et al., 2000; Sarnacki et al., 2000) and
to the 2 I-like domain in L2 and M2 holoreceptorsdramatically alleviate the symptoms of psoriasis in clini-
(Welzenbach et al., 2002). Here we demonstrate thatcal trials (Gottlieb and Bos, 2002; Gottlieb et al., 2002).
these inhibitors represent a novel class of antagonistsLeukocyte integrins contain one von Willebrand fac-
tor-type A domain in each subunit, the inserted (I) do- of I domain-containing integrins, which bind to the 2
main in the  subunit and the I-like domain in the  I-like domain MIDAS near a key regulatory interface with
subunit (Shimaoka et al., 2002). Each domain adopts an the L and M subunits, and block communication of
conformational change to the I domain, while at the
same time activating conformational rearrangements*Correspondence: springeroffice@cbr.med.harvard.edu (T.A.S),
shimaoka@cbr.med.harvard.edu (M.S.) elsewhere in integrins.
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Figure 1. Chemical Structures of Small Molecule Integrin Inhibitors
(A) / I-like allosteric inhibitors to the 2 integrin and comparison to / I-like competitive inhibitors to 41. Compounds #1, #3, and #4 are
as described (Gadek et al., 2002); compound #5 (XVA143) is identical to example 345 (Fotouhi et al., 1999) (Welzenbach et al., 2002); the
Tanabe and other 41 antagonists are described (Jackson, 2002).
(B)  I allosteric inhibitors are shown for comparison: BIRT377 (Last-Barney et al., 2001), LFA703 (Weitz-Schmidt et al., 2001), and A-286982
(Liu et al., 2001).
Results some selectivity of compound #4 was evident for LFA-1,
because compounds #4 and #5 inhibited L2 equally
well but compound #4 was less potent than #5 againstInhibition of Both L2 and M2 by Compounds #3,
#4, and #5 M2 (Figures 2A and 2B). By contrast to compounds
#3, #4, and #5, the L I domain allosteric inhibitorsXVA143 (compound #5, Figure 1A) and many related
compounds patented by Roche inhibit both L2 and BIRT377 and LFA703 (Figure 1B) blocked exclusively
L2 (Figures 2A and 2B and data not shown).M2 (Fotouhi et al., 1999; Welzenbach et al., 2002). The
Genentech compounds #3 and #4 (Figure 1A) and the In the mixed lymphocyte reaction (MLR), the L2-
ICAM-1 interaction transmits costimulatory signals forRoche compounds are closely structurally related and
are derived by optimization of the same drug discovery proliferation. Remarkably, compound #5 compares in
potency with the immunosuppressive drug cyclosporinlead, compound #1 (J. Tilley, Roche, Nutley, NJ, per-
sonal communication) (Gadek et al., 2002). The Genen- A in its ability to inhibit the MLR (Figure 2C). Compounds
#3 and #4 have previously also been shown to inhibittech compounds have been reported to inhibit L2;
however, the results of M2 inhibition assays have not the MLR (Gadek et al., 2002). Thus, the class of antago-
nists that includes compounds #3, #4, and #5 are potentyet been disclosed in the research or patent literature
(Burdick, 1999; Burdick et al., 2001; Gadek et al., 2002). inhibitors of lymphocyte functional responses that re-
quire LFA-1 and also act as dual LFA-1 (L2) and Mac-1We tested the hypothesis that Genentech compounds
#3 and #4 would inhibit M2 as well as L2 (Figures 2A (M2) antagonists.
and 2B). Compounds #3 and #4 inhibited M2 binding
to iC3b with IC50 values of 3  1 and 0.1  0.01 M, Allosteric Inhibition by Compounds #3, #4, and #5
The mode of action of inhibitors was studied by usingrespectively. Compound #5 had an IC50 value of 0.06 
0.01M in the same assay, extending previous inhibition L2 containing a mutant I domain, which is reversibly
locked in the open, high-affinity conformation withdata on the M2 interaction with fibrinogen and ICAM-1
to the M2 interaction with iC3b. Thus, all of the tested K287C and K294C mutations to introduce cysteines that
form an engineered disulfide bond (locked open I do-compounds inhibited both L2 and M2. Compound #3
was less potent than #4 and #5 with both integrins, and main) (Lu et al., 2001c). Adhesion through L2 con-
Novel Mechanism for 2 Integrin Antagonism
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Figure 2. Inhibition by Compounds #3–#5 of
L2 and M2
(A and B) Adhesion of L2-expressing K562
cells to immobilized ICAM-1 (A) and M2-
expressing cells to immobilized iC3b on plas-
tic (B) was as described (Lu and Springer,
1997; Shimaoka et al., 2000). L2 was acti-
vated by 1 mM Mn2, and M2 was activated
by 1 mM Mn2 in the presence of 2 g/ml
CBR LFA-1/2. Values are % inhibition of
mock-treated cells and expressed as mean
difference from the mean of two independent
experiments. Specific binding of cells in the
absence of inhibitors was 44.4  1.8% and
52.8  1.5% of input for L2 and M2
transfectants, respectively.
(C) Compound #5 and cyclosporin A inhibit
the mouse MLR. Inhibition of [3H]thymidine
incorporation was measured as described in
the Experimental Procedures. A representa-
tive experiment out of two independent ex-
periments is shown.
(D and E) Defining the mechanism of inhibition
of small molecule antagonists using L2 het-
erodimers containing mutant L I domains.
Binding of soluble ICAM-1-IgA/FITC anti-IgA
to K562 transfectants expressing L2 con-
taining wild-type (WT) or the mutant high-
affinity (HA) I domain in the presence of 1 mM
MnCl2. The binding assay was performed at
room temperature in the absence (D) or pres-
ence (E) of 10 mM DTT. Results are mean 
SD of three independent experiments.
taining the locked open I domain can be inhibited by containing the K287C/K294C mutant I domain became
susceptible to both classes of small molecule inhibitorsmAbs that map to the ICAM-1 binding site of the L I
domain, but not by mAbs that map to other sites in the (Figure 2E).
L I domain, or mAbs that map to the 2 I-like domain
(Lu et al., 2001c). By contrast, wild-type L2 and locked Lack of Inhibition by Compounds #3–#5
of the Isolated L I Domainopen L2 treated with dithiothreitol (DTT) to reduce the
introduced disulfide bond and allow the I domain to shift Compounds #3, #4, and #5 were further tested for their
ability to inhibit binding of the isolated, soluble L I do-to the closed conformation can be completely inhibited
by both classes of mAbs to the L I domain and the main to ICAM-1. In addition to the K287C/K294C high-
affinity mutant L I domain (Shimaoka et al., 2001), wemAbs to the 2 I-like domain (Lu et al., 2001c). Similarly,
the  I domain allosteric antagonists lovastatin and used the L161C/F299C intermediate-affinity mutant L I
domain (Shimaoka et al., 2003). Crystal structures ofLFA703 cannot inhibit locked open L2 but do inhibit
wild-type L2 and DTT-treated K287C/K294C mutant both of these mutant I domains have been determined,
including the intermediate-affinity L I domain boundL2 (Lu et al., 2001c; Salas et al., 2002). Thus, competitive
antagonists to the ICAM-1 binding site in the L I domain to ICAM-1 (Shimaoka et al., 2003). Furthermore, two
different crystal forms of the mutant high-affinity L Iand noncompetitive antagonists that bind elsewhere in
L2 can be discriminated using locked open L2. domain demonstrate that even in the absence of
ICAM-1, its ligand binding site surrounding the MIDASCompounds #3, #4, and #5 blocked binding to ICAM-1
of L2 containing the wild-type I domain but not L2 is locked into the same conformation as seen when
ICAM-1 is bound (Shimaoka et al., 2003). We testedcontaining the locked open I domain (Figure 2D). Similar
results were obtained with the I domain allosteric inhibi- binding of these mutant I domains to ICAM-1 using sur-
face plasmon resonance (Figures 3A–3J). The plasmontors LFA703 (Figure 2D) and BIRT377 (data not shown).
By contrast, both wild-type and mutant L2 were com- resonance curves in the absence of inhibitors (Figures
3A and 3F) and the amount of inhibition by solublepletely blocked by the direct inhibitor mAb TS2/6 to the
I domain (data not shown). After mild DTT reduction, L2 ICAM-1 (Figures 3E and 3J) were consistent with previ-
Immunity
394
Figure 3. Lack of Inhibition by Compounds #3–#5 of L I Domain Binding to ICAM-1
(A–J) Surface plasmon resonance analysis of binding by the L I domains to ICAM-1. The high-affinity (K287C/K294C) or the intermediate-
affinity (L161C/F299C) I domain was perfused onto immobilized ICAM-1 in the presence of 100 M of compound #3 (B and G), #4 (C and H),
#5 (D and I), or 0.55 (E) or 1.1 M (J) of soluble ICAM-1. DMSO (1:1000), the vehicle for compound #5, and BSA (100 g/ml), the control for
ICAM-1, had no effect on I domain binding (data not shown).
(K) Detachment in shear flow of transfectants bound to ICAM-1 substrates. K562 transfectants expressing the isolated wild-type L domain
were incubated with or without 100 M compounds or 10 g/ml Fab fragment of TS1/22 for 10 min at RT in Hank’s balanced salt solution,
1 mM Mg2, 1 mM Ca2, infused in the flow chamber, and allowed to settle on the ICAM-1 substrate for 5 min, and the wall shear stress was
then increased in steps every 10 s as shown (Salas et al., 2002). Cells interacting with the ICAM-1 substrate, including both firmly adherent
and rolling cells, were counted and expressed as percentage of input at the end of each 10 s interval.
ous measurements of the KD for ICAM-1 of 150 nM for flow, where force exerted on the C terminus of the I
domain helps stabilize it in the high-affinity conformationthe high-affinity I domain and 3 M for the intermediate-
affinity I domain (Shimaoka et al., 2001, 2003). Com- (Salas et al., 2002). Rolling of transfectants on ICAM-1
substrates was blocked by TS1/22 Fab to the I domainpounds #3, #4, and #5 had no effect on binding of high-
affinity (Figures 3A–3D) or intermediate-affinity (Figures and by the I domain allosteric antagonist compounds
LFA703 and BIRT377 but not by compounds #3, #4, and3F–3I) I domains to immobilized ICAM-1, despite use of
the compounds at 100 M, a concentration 104 to 105 #5 (Figure 3K and data not shown). Differential inhibition
of rolling mediated by the isolated L I domain thushigher than the compounds’ reported IC50 values for
inhibition of intact L2 (Fotouhi et al., 1999; Gadek et distinguishes between these two classes of LFA-1 an-
tagonists. Compounds #3, #4, and #5 clearly fail to in-al., 2002). By contrast, soluble ICAM-1 used at 0.55 M
with the high-affinity I domain (Figure 3E) or 1.1 M with hibit binding of ICAM-1 to the mutant locked open L2
holoreceptor, to mutant soluble high-affinity and inter-the intermediate-affinity I domain (Figure 3J) markedly
inhibited binding to immobilized ICAM-1. mediate I domains, and to the isolated wild-type I do-
main on cell surfaces. These findings demonstrate thatTo test the effect of the compounds on ligand binding
by the wild-type L I domain, the isolated L I domain compounds #3, #4, and #5 do not mimic ICAM-1.
was fused to an artificial transmembrane domain and a
5 residue cytoplasmic domain and expressed on K562 Stabilization of / Subunit Association
Inhibitors of integrins that lack I domains, such as thosetransfectants (Lu et al., 2001b). Interaction with ICAM-1
of the isolated wild-type L I domain is most readily that are based on the Arg-Gly-Asp (RGD) sequence,
bind to both the integrin  and  subunit. The Asp car-detected by its ability to support rolling of cells in shear
Novel Mechanism for 2 Integrin Antagonism
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boxylic acid side chain coordinates directly to the metal possible to build  subunit specificity into the com-
of the  subunit I-like domain MIDAS, while the Arg side pounds, as is indeed illustrated by the compound series.
chain binds to the subunit-propeller domain (Xiong et Compound #5 stabilizes L2 and M2 complexes with
al., 2002). Several of this class of antagonists to integrins equal potency, both in Mg2/Ca2 and in Mn2 (Figure
that lack I domains have been shown to stabilize  4D). Compound #4 was equipotent in stabilizing L2
association sufficiently to make it resistant to SDS at and M2 in Mn2; however, it was 50-fold more potent
room temperature (Thibault, 2000; Zolotarjova et al., in stabilizing L2 than M2 in Mg2/Ca2 (Figure 4D).
2001). Compounds #3, #4, and #5 (Figure 1A), but not I Finally, compound #3 was 100-fold more potent in stabi-
domain allosteric antagonists such as LFA703 (Figure lizing L2 than M2 in Mn2, and the difference in po-
1B), resemble non-I domain integrin antagonists in the tency increased to 1000-fold in Mg2/Ca2 (Figure 4D).
absolute requirement for a free carboxyl group and often On the basis of the evidence that compounds #3–#5
in other structural features as well. We reasoned that if bind to the 2 I-like MIDAS, stabilize  association, and
compounds #3–#5 bound to a similar site they might can show selectivity for the  subunit, we propose to
also stabilize the  integrin complex to SDS. In the call them / I-like allosteric antagonists. We propose
absence of added compounds, L2 was dissociated by the designation  I allosteric antagonists for the other
SDS, and the L and 2 subunits migrated individually class of inhibitors to the I domain.
in SDS-PAGE, in both reducing and nonreducing condi-
tions (Figure 4A, lanes 1 and 6). By contrast, when Impacts on Integrin Conformation
treated with compounds #3–#5, but not with LFA703, In order to obtain further mechanistic insights into the
an SDS-stable L2 complex was formed, and no free / I-like allosteric antagonists, their impacts on integrin
L or 2 subunit was present (Figure 4A, lanes 2–5). conformation were studied using purified recombinant
Identical results were obtained after reduction with DTT and cell surface L2. We tested three activation-depen-
(Figure 4A, lanes 7–9). Stabilization by the inhibitors to dent mAbs mapped to distinct sites. The m24 epitope
SDS treatment required divalent cations because EDTA maps to the 2 I-like domain, and its exposure shows
abolished complex formation (Figures 4A, lanes 11–13, that the I-like domain is activated (Dransfield and Hogg,
and 4D). 1989; Lu et al., 2001c). The KIM127 epitope involves
Stabilization of mutant  complexes was utilized to residues in integrin EGF domain 2 in the 2 subunit that
test compound binding to L2 mutants and locate the are buried in the headpiece-tailpiece interface in the
inhibitor binding site. Compounds #3–#5 formed SDS- bent integrin conformation and exposed in the extended
stable  complexes with L2 containing the mutant conformation (Beglova et al., 2002; Lu et al., 2001a). The
locked open I domain (Figure 4B, lanes 3 and 4), demon- NKI-L16 epitope maps to the thigh domain and genu of
strating that, despite their lack of ability to inhibit binding the L leg (Huang and Springer, 1995) (C. Xie and T.A.S.,
to ICAM-1, they bind to locked open L2. Furthermore, unpublished data), and its exposure is associated with
compounds #3–#5 stabilized association in SDS of L2 activation (van Kooyk et al., 1991). The exposure of these
with the I domain deleted from the L subunit (I-less, epitopes is usually induced by inside-out signaling as
Figure 4B, lanes 7 and 8) (Yalamanchili et al., 2000), well as ligand binding. Remarkably, the / I-like alloste-
demonstrating that the L I domain is not required for ric antagonists potently induced m24, KIM127, and NKI-
compound binding. Quantitative analysis further dem- L16 epitope expression in L2 (Figures 5A and 5B andonstrated that EC50 values for compound binding to wild- Table 1). By contrast, the  I domain allosteric antago-
type L2, L2 containing the high-affinity I domain, and nists BIRT377 (Table 1) and LFA703 (data not shown)
I-less L2 are indistinguishable (Figures 4C and 4D). To did not enhance KIM127 and m24 epitopes expression.
test whether the MIDAS of the 2 I-like domain was To the contrary, these compounds suppressed induc-
required for binding, we mutated one of the metal-coor-
tion of activation epitopes by Mn2 (Woska et al., 2001)dinating side chains in 2, Ser114, to Ala. Although the (Table 1). Induction by / I-like allosteric antagonists
L and mutant2 chains were well expressed and nonco- of the KIM127 epitope was divalent cation dependent,valently associated prior to SDS addition, as demon-
as shown by inhibition by EDTA, whereas activatingstrated by coprecipitation with mAb TS2/4 (Figure 4B,
mAb CBR LFA-1/2 induced KIM127 expression in thelane 5), none of the compounds stabilized SDS-resistant
presence of EDTA (Figure 5C). Consistent with previous complexes with the 2-S114A mutant (Figure 4B, lane
results (Welzenbach et al., 2002), binding of the 2 I-like6), demonstrating the crucial role of the 2 MIDAS in the
domain mAbs, TS1/18 and IB4, was reduced by  action of these compounds. In all cases, compound
I-like antagonists (Figure 5A and Table 1). Induction ofbinding was dependent on metal ions, and both Ca2/
activation-dependent epitopes by the antagonists wasMg2 and Mn2 were permissive for complex formation
also observed with L2 containing the locked open I(Figure 4D). Interestingly, compound #3 stabilized com-
domain and with I-less L2, but not with the L2-S114Aplex formation better in Mn2 than Mg2/Ca2 (Figure
mutant (Figure 5D). These results confirmed that the L4D), again showing the importance of metal ions for
I domain is not required and that the 2 I-like MIDAS iscompound binding.
required for compound activity.The ability to stabilize  association and the lack of
requirement for the  I domain suggest that compounds
Discussion#3–#5 may bridge the 2 I-like domain MIDAS to the 
subunit -propeller domain. The -propeller shares an
Regulation of L2 activation is a pivotal process forextensive interface with the I-like domain and comes
controlling leukocyte trafficking and immune responsesclose to its MIDAS in the three-dimensional structure
(Xiong et al., 2001; Zang et al., 2000). Thus, it should be in health and diseases (Anderson et al., 1989; Harlan et
Immunity
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Figure 4. Effect of Compounds on L2 Mutants and M2 Measured by Stabilization of  Complexes in SDS-PAGE
(A) SDS-PAGE and Coomassie blue staining of soluble recombinant L2 in the presence or absence of the inhibitors and 10 mM DTT.
(B) Immunoprecipitation of wild-type and mutant L2 heterodimers. Lysates of surface-biotinylated K562 cell transfectants, which were
pretreated with inhibitors (100 M) or DMSO (1:1000), were immunoprecipitated with mAb TS2/4 to L2 and detected on Western blots by
streptavidin and luminescence.
(C) Dose response for formation of the SDS-stable  complex by wild-type and mutant L2. Lysates from transfectants, adjusted to contain
35 pM of L2, were incubated with the indicated concentrations of the inhibitors. The complexed and free 2 subunit was detected by Western
blotting with mAb CBR LFA-1/2. Representative Western blots are shown. Because of its larger size, the  complex is transferred less
efficiently out of the gel than free , resulting in weaker maximal intensity.
(D) EC50 values for complex stabilization by the inhibitors. Values were calculated from experiments performed identically to those shown in
Figure 3C. L2 complex and free 2 were quantitated by NIH image software, the differences in maximal intensity of L2 and free 2 were
normalized using conditions in which only L2 or free 2 were present, and the free 2 was calculated as % of total normalized L2 and free
2 in each lane. Results are mean and difference from the mean of two independent experiments. 1000, no complex stabilization seen at 1
mM compound. The ability of compound #3 to stabilize M2 in Mg2 and Ca2 was confirmed by complete stabilization of recombinant,
purified M2 with 10 mM compound #3.
Novel Mechanism for 2 Integrin Antagonism
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Figure 5. Effect of Compounds on Expression of Activation Epitopes
(A–C) Recombinant soluble L2. (A) Induction of activation epitopes and partial inhibition of expression of 2 I-like domain epitopes by
compound #5. Soluble L2 indirectly captured onto plastic with antibody to the C-terminal coiled-coil tag was incubated with mAbs (2 g/
ml) in HBS, 1 mM MgCl2, 1 mM CaCl2 in the presence of 10 M compound #5 or 1:10,000 DMSO. Binding of mAbs was detected by peroxidase-
labeled secondary antibody. Results are mean  SD of three independent experiments (A–C). (B) Dose-dependent induction of KIM127 and
m24 activation epitopes by compounds #4 and #5. (C) Divalent cation-dependence of KIM127 epitope induction.
(D) Induction of epitopes of L2 mutants on K562 cell transfectants. Cells were stained with mAbs (2 g/ml) in HBS, 1 mM MgCl2, 1 mM
CaCl2, containing compound #5 (1M) or DMSO at 37C for 30 min, followed by immunofluorescence flow cytometry. Representative histograms
and mean values of fluorescence intensity in three independent experiments are shown. Binding of the positive control TS2/4 mAb (filled
histogram) and nonbinding IgG (open histogram) are shown in the upper panels. Compound #5 failed to enhance KIM127 and m24 epitopes
in mutant 2 S114A; these epitopes were induced in the same mutant by activating mAb CBR LFA-1/2 (data not shown).
al., 1992; Springer, 1990). Upon integrin activation, the 2002). While these compounds are potent antagonists
of wild-type L2, they fail to inhibit binding to ICAM-1affinity of the ligand binding I domain is allosterically
regulated by an axial downward displacement of its of L2 containing a mutant I domain locked in the high-
affinity conformation with a disulfide bond. These com-C-terminal helix, which is proposed to be induced by a
neighboring regulatory domain, the I-like domain (Shi- pounds also fail to inhibit binding to ICAM-1 of soluble,
mutant intermediate or high-affinity I domains as shownmaoka et al., 2002, 2003). Transmission of conforma-
tional signals through regulatory domains (e.g., the I-like by surface plasmon resonance, or binding to ICAM-1 of
the isolated, surface-displayed, wild-type I domain asdomain) to the I domain is a key step in integrin activation
and a novel target for development of allosteric inhib- shown by cell rolling assays in shear flow. The same
results were obtained with compound #5, a representa-itors.
Here, we report a novel mechanistic class of antago- tive of a structurally closely related group of compounds
patented by Roche (Fotouhi et al., 1999, 2001). Allostericnists to integrins that contain I domains that we term
/ I-like allosteric antagonists. Interestingly, we have antagonists that bind underneath the C-terminal  helix
of the L I domain such as LFA703 and BIRT377 alsofound that the small molecule compounds #3 and #4
reported by Genentech to antagonize ICAM-1 binding blocked wild-type L2 but not L2 containing the mu-
tant high-affinity I domain. Crystal structures of the mu-to integrin L2 are not ligand mimetics that function
competitively as originally suggested (Gadek et al., tant high-affinity L I domain demonstrate that it is stabi-
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Table 1. Effects of Small Molecule Inhibitors on mAb Binding
Mg2  Ca2 Mn2
Mean Fluorescence Intensity
mAb Epitope DMSO Comp. #5 BIRT377 DMSO Comp. #5 BIRT377
TS1/22 L I domain 113  4 116  3 109  3 120  3 121  3 109  3
R7.1 L I domain 143  5 136  4 28  3 147  8 143  3 34  3
TS2/4 L -propeller 127  3 118  4 124  3 136  2 128  3 130  4
NKI-L16a L thigh/genu 108  10 156  5 111  3 81  5 154  7 55  5
TS1/18 2 I-like domain 114  5 92  4 112  3 79  2 17  3 77  3
IB4 2 I-like domain 138  9 127  8 139  4 139  5 80  6 139  3
m24a 2 I-like domain 7 1 140  5 3  1 142  7 152  3 51  6
KIM127a 2 I-EGF2 6  1 86  7 3  1 92  2 98  3 29  4
CBRLFA-1/2 2 I-EGF3 110  4 108  7 110  2 111  5 107  6 117  3
Cells were stained with mAbs (2 g/ml) in HBS with 1 mM MgCl2 and 1 mM CaCl2, or with 1 mM MnCl2, in the presence of compound #5
(1 M), BIRT377 (10 M), or DMSO (1:1000) at 37 C for 30 min, followed by immunofluorescence flow cytometry. Values are means  SEM
of three independent experiments. Values significantly different from the DMSO control are underlined.
a Activation-dependent antibody.
lized in the same open, high-affinity conformation that 2 integrins share chemical and functional properties
with ligand-mimetic, / I-like competitive antagonistsis seen when the L I domain is bound to ICAM-1 (Shi-
maoka et al., 2003). Thus, compounds #3–#5, BIRT377, to integrins V3, IIb3, and 41 that lack an I domain.
RGD-mimetic competitive antagonists of V3 and IIb3and LFA703 do not compete for the ICAM-1 binding
site. However, compounds #3–#5 clearly bind to a site induce exposure of activation epitopes (Du et al., 1991;
Peter et al., 2001). This is a consequence of the confor-distinct from BIRT377 and LFA703, as demonstrated by
the ability of BIRT377 and LFA703 but not compounds mational change induced in the I-like domain that results
in a movement at its interface with the hybrid domain,#3–#5 to inhibit interactions of the wild-type, isolated,
surface-expressed I domain with ICAM-1 substrates in and conversion of the low-affinity, bent integrin confor-
mation to the high-affinity, extended conformation (Ta-shear flow.
Further studies emphasize the similarities in the mode kagi et al., 2002). Exposure of epitopes in the I-like do-
main,  subunit genu, and  subunit I-EGF-2 domainof action of compounds #3 and 4 from Genentech and
compound #5 from Roche, their distinction from L I suggests that / I-like allosteric antagonists induce a
similar conformational change in L2 (Figure 6). Re-domain allosteric antagonists, and define the binding
site for compounds #3–#5. We find that compounds #3 markably, a number of 41 integrin antagonists are
chemically similar to compounds #3–#5 in being poly-and #4 inhibit M2 in addition to L2, as previously
described for compound #5. Compound #5 inhibits the substituted (S )-2-benzoylamino propionic acids (Figure
1A); indeed, compounds #3–#5 were developed fromMLR, as previously described for compounds #3 and
#4. Compounds #3–#5 induce activation epitopes on compound #1, which was initially recognized as an 41
antagonist and later found to inhibit L2 (J. Tilley, per-L2, whereas LFA703 and BIRT377 suppress epitope
induction by Mn2. Compounds #3–#5, but not LFA703 sonal communication). We propose that the / I-like
antagonists to integrins that lack and contain I domainsor BIRT377, stabilized association between the L and
2 subunits of LFA-1 and the M and 2 subunits of Mac-1 act analogously, except that they inhibit binding to ex-
trinsic ligands and intrinsic ligands, respectively. Thein SDS-PAGE. The binding site for compounds #3–#5
does not include the I domain because studies with polypeptide linker between the C terminus of the I do-
main and  sheet 3 of the -propeller domain includingmutant L2 receptors from which the I domain was
deleted showed that these compounds still stabilized L residue Glu310 has been shown to be important in I
domain activation (Huth et al., 2000). I domain activationassociation between the L and 2 subunits and induced
exposure of activation epitopes. In contrast, the com- is induced by a downward pull on the C-terminal  helix
or linker (Salas et al., 2002; Shimaoka et al., 2002, 2003).pounds did not stabilize L2 association or induce acti-
vation epitopes when residue Ser114 of the 2 MIDAS Binding of the activated 2 I-like domain to the “intrinsic
ligand” L Glu310 has been proposed to pull thewas mutated to Ala, strongly suggesting that the 2
MIDAS forms part of the binding site for these com- C-terminal  helix of the L and M I domains downward
and activate high affinity for ligand (Alonso et al., 2002;pounds. Since the  subunit -propeller domain and the
linker segments between the -propeller domain and I Shimaoka et al., 2002; Takagi and Springer, 2002). The
induction of activation-dependent epitopes by the /domain are near the 2 MIDAS in the integrin three-
dimensional structure, and some compounds differ in I-like allosteric antagonists described here suggests
that they act as intrinsic ligand-mimetics that bind toaffinity for L2 and M2, the  subunit may also partici-
pate in selectivity. Therefore, we designate compounds the 2 MIDAS, stabilize the I-like domain in the liganded
state, and induce the switchblade-like opening that re-#3–#5 “/ I-like allosteric antagonists,” in contrast to
LFA703 and BIRT377 which are  I allosteric antago- sults in conversion of the bent to extended integrin con-
formation (Figure 6). Thus, the interface between thenists.
The / I-like allosteric antagonists described here to I domain linker and the I-like domain appears to be
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Figure 6. Model for Conformational States of the Extracellular Domain of L2
The models for all of the extracellular domain except for the I domain (Springer, 2002) are based on conformational states of V3 and L2
defined by negative stain electron microscopy (Takagi et al., 2002), crystallography (Xiong et al., 2002), NMR (Beglova et al., 2002), and
mapping of activation epitopes (Lu et al., 2001a, 2001c). The L I domain and its complex with ICAM-1 are cartoons based on crystal structures
(Shimaoka et al., 2003); the C-terminal I domain  helix is represented by a cylinder. The I domain is joined at the point of its insertion in the
-propeller domain, but its orientation is arbitrary; the I domain and ICAM-1 are shown at slightly larger scale for emphasis. The orientation
of all other domains is based on three distinct conformations of V3 visualized by electron microscopy (Springer, 2002; Takagi et al., 2002).
Regions to which activation epitopes map are circled. The metal ions at the MIDAS of the I and I-like domains are shown as gold spheres.
(A) Bent conformation with low affinity. This conformation is stabilized by bound  I allosteric antagonists, symbolized by three cyan spheres.
(B) Extended conformation with closed headpiece. This conformation is in equilibrium with the bent conformation and is stabilized by Mn2
as shown with V3 (Takagi et al., 2002).
(C) Extended conformation with open headpiece induced by bound / I-like allosteric antagonist (symbolized by three red spheres), which
blocks conformational communication to the I domain and leaves it in the low-affinity state. The extended conformation with the open
headpiece is induced by / I-like competitive antagonists to V3 (Takagi et al., 2002).
(D) Extended conformation with open headpiece, high-affinity I domain, and bound ICAM-1. Both activation signals from within the cell and
binding to ICAM-1 stabilize this active, high-affinity conformation.
important to convey bidirectional activation signals be- mation. The results of this study highlight a pathway of
interdomain communication between I and I-like do-tween the I and I-like domains.
Interestingly, the integrin 1 subunit associates both mains as a novel target for integrin antagonism.
with subunits that lack and contain I domains. Antibod-
Experimental Proceduresies to the I domains of the 11 and 21 integrins effec-
tively block animal models of autoimmune diseases (de
Cells
Fougerolles et al., 2000), yet small molecule antagonists K562 transfectants expressing wild-type and mutant L2, M2, and
have not yet been reported. Our findings suggest that isolated L I domain were described (Lu et al., 2001b). cDNAs encod-
it should be possible to develop / I-like allosteric ing 2 S114A mutations were constructed and subcloned in pcDNA
3.1 ()/neo (Invitrogen) by standard molecular biology techniques.antagonists of 11 and 21 integrins starting from /
The plasmids containing 2 S114A were cotransfected with vectorI-like competitive antagonists of 41.
containing wild-type L subunit into K562 cells and selected with 1The / I-like allosteric antagonists inhibit I domain
mg/ml G418 (Lu and Springer, 1997).
activation, whereas they stabilize the rest of the integrin
in the active conformation. The antagonists appear to Small Molecule Inhibitors
block ligand binding by a novel mechanism, in which Compound #5 (XVA143) (Welzenbach et al., 2002) was synthesized
according to example 345 of the patent (Fotouhi et al., 1999) andthey competitively inhibit binding of the I domain linker
was also obtained from Dr. Paul Gillespie (Roche, Nutley, NJ). Com-to the I-like domain and leave the I domain in the default
pounds #3 and #4 were obtained from Genentech (South San Fran-inactive closed conformation (Figure 6). At the same
cisco, CA) through the research reagents program (http://www.gene.time, the / I-like inhibitors stabilize the I-like domain
com/gene/about/collaborations/contracts.jsp). LFA703 (Weitz-Schmidt
in its active configuration, mimicking internal ligand et al., 2001) was from Novartis Pharma AG (Basel, Switzerland),
binding to the 2 MIDAS, and as a consequence of I-like and BIRT377 (Last-Barney et al., 2001) was from Dr. Terence Kelly
(Boehringer Ingelheim Pharmaceuticals Inc, Ridgeway, CT).domain activation stabilize the extended integrin confor-
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Mouse Mixed Lymphocyte Reaction labeled goat anti-mouse antibody and substrate. In some experi-
ments that included EDTA and activation by mAb CBRLFA-1/2, bio-The two-way murine MLR was as described (Grassberger et al.,
1999). In brief, single-cell suspensions were isolated from the tinylated KIM127 and TS2/4 as a control were used and detected
by peroxidase-streptavidin and substrate.spleens of CBA (H-2k) and BALB/c (H-2d) mice, mixed, and incubated
with serial dilutions of test compounds for 4 days at 37C. [3H]thymi-
dine was added and incubated for 16 hr. Cells were harvested on SDS-PAGE
filter paper, and radioactivity was counted after the addition of scin- Soluble LFA-1 (5 l, 0.2 mg/ml) was incubated in HBS containing
tillation fluid. The background reading from proliferation of BALB/c 10 M inhibitors, or DMSO (1:10000) in the presence of 1 mM MgCl2,
cells alone was subtracted from all values. The proliferation of mixed 1 mM CaCl2 or 5 mM EDTA at room temperature for 10 min. Sample
cells in absence of compound was taken as the maximum activity buffer containing 0.2% SDS with or without 10 mM DTT (5 l) was
(100%). The test compounds were dissolved in DMSO and then added, mixed, and incubated 5 min at room temperature. Samples
further diluted in assay buffer. were subjected to Tris-Glycine SDS 7.5% PAGE (BioWhittaker Mo-
lecular Applications, Rockland, ME), and stained with Coomassie
brilliant blue R.Binding of Soluble ICAM-1
K562 transfectants were harvested, dispensed to 5 ml polystyrene
tubes (Becton Dickinson) (1  105 cells/tube), and washed once Immunoblotting
with HEPES-buffered saline (HBS), 10 mM EDTA, and three times K562 transfectants were washed with Hank’s balanced salt solution
with HBS. Cells were incubated in 50 l of HBS in the presence or (HBSS), 1 mM MgCl2, 1 mM CaCl2. Cells (2  107 /ml) were lysed
absence of 10 mM DTT at room temperature for 10 min. Then, 50 with an equal volume of 2 lysis buffer (HBSS, 2% Triton X-100,
l HBS containing 20 g/ml ICAM-1-IgA fusion protein (Martin et al., 0.2% NP-40, 1 mM MgCl2, 1 mM CaCl2) supplemented with protein-
1993), 100 g/ml FITC-labeled anti-human IgA polyclonal antibody ase inhibitors (complete EDTA-free, Roche), incubated for 15 min
(Pierce), 2 mM MnCl2, and small molecule inhibitors, inhibitory anti- on ice, and centrifuged at 14,000 rpm for 15 min. Supernatant was
bodies, or appropriate controls were added. For control, ICAM-1- collected, the concentration of L2 was measured by ELISA using
IgA fusion protein was replaced with purified human IgA at the same recombinant soluble LFA-1 as standard, the concentration was ad-
concentration. Cells were further incubated at room temperature justed to 35 nM with 1 lysis buffer, and stored at 	80C. Lysate
for 20 min and washed once by 4 ml of HBS and resuspended in samples diluted to 35 pM with HBS containing 1 mM MgCl2/CaCl2,
100 l HBS containing 2% paraformaldehyde. Binding of ICAM-1- 1 mM MnCl2, or 1 mM EDTA were incubated with inhibitors at room
IgA was analyzed by flow cytometry. temperature for 10 min. Samples were mixed with SDS-sample
buffer and subjected to nonreducing SDS-PAGE as described
above, and proteins were blotted to PVDF membrane (Bio-Rad).Surface Plasmon Resonance
Blots were probed with 1 g/ml CBR LFA-1/2 antibody to 2, thenThe high-affinity (K287C/K294C) or the intermediate-affinity (L161C/
with peroxidase-goat anti-mouse IgG (Petruzzelli et al., 1995), andF299C) I domain was perfused into a CM-5 chip bearing immobilized
visualized by luminescence (Lumi Glo, New England Biolabs, Bev-ICAM-1 or BSA in Tris-buffered saline containing 2 mM MnCl2 at a
erly, MA).flow rate of 10 l/min at 25C as described (Shimaoka et al., 2003).
I domains were preincubated with 100 M of the antagonists or
0.55 or 1.1 M of soluble ICAM-1 in the same buffer for 30 min at Cell Surface Biotinylation and Immunoprecipitation
room temperature and perfused onto the chip in a BIAcore 2000 K562 transfectants washed with HBSS, 1 mM MgCl2, 1 mM CaCl2
instrument. The background response on the BSA surface is sub- (2 107 /ml) were incubated with 100M inhibitors or DMSO (1:1000)
tracted from each sensorgram. as control at 4C for 30 min. Cell surface proteins were labeled with
biotin by adding 0.5 mg/ml of Sulfo-NHC-LC-biotin (Pierce) for 1 hr
at 4C with rotation. Cells were washed three times with HBSS, 5Controlled Detachment in Shear Flow
mM Tris HCl (pH 7.4), 1 mM MgCl2, 1 mM CaCl2, and resuspendedDetachment in shear flow of transfectants bound to ICAM-1 sub-
in the same buffer containing the appropriate inhibitor at 2  107strates was as described (Salas et al., 2002).
cells/ml. Cell lysates were prepared as described above and sub-
jected to immunoprecipitation with mAb TS2/4 to L2 and proteinImmunofluorescent Cytometry
A agarose (Pharmacia). The protein A beads were washed withImmunofluorescent cytometry was as described (Lu et al., 2001a;
Tris-buffered saline, 1 mM MgCl2, 1 mM CaCl2 containing 100 nMLu and Springer, 1997). KIM127, m24, and NKI-L16 antibodies were
inhibitors or 0.0001% DMSO. Beads were incubated with samplekindly provided by M. Robinson, N. Hogg, and Y. van Kooyk, respec-
buffer containing 0.2% SDS at room temperature for 5 min andtively.
centrifuged at 14,000 rpm for 30 s. Supernatant was subjected to
SDS-PAGE and blotting as described above. Blots were probedSoluble Recombinant LFA-1
with peroxidase-streptavidin and visualized by luminescence as de-cDNAs encoding extracellular domains of L (residues 1 to 1063)
scribed above.and 2 (residues 1 to 678) subunits fused to the N terminus of ACID
and BASE -helical coiled coils, respectively, were constructed and
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